neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Company profile
Ticker
NBIX
Exchange
Website
CEO
Kevin Gorman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Neurocrine Continental, Inc. • Neurocrine International, Inc. • Neurocrine Europe, Ltd. • Neurocrine Therapeutics, Ltd. • Neurocrine UK Limited • Neurocrine Switzerland GmbH • Diurnal Group Limited • Diurnal Limited • Diurnal Europe B.V. ...
IRS number
330525145
NBIX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
10-K
2023 FY
Annual report
9 Feb 24
8-K
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
7 Feb 24
8-K
Other Events
13 Nov 23
8-K
Other Events
9 Nov 23
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
31 Oct 23
8-K
Other Events
6 Oct 23
Transcripts
NBIX
Earnings call transcript
2023 Q4
7 Feb 24
NBIX
Earnings call transcript
2023 Q3
31 Oct 23
NBIX
Earnings call transcript
2023 Q2
1 Aug 23
NBIX
Earnings call transcript
2023 Q1
3 May 23
NBIX
Earnings call transcript
2022 Q4
6 Feb 23
NBIX
Earnings call transcript
2022 Q3
1 Nov 22
NBIX
Earnings call transcript
2022 Q2
5 Aug 22
NBIX
Earnings call transcript
2022 Q1
4 May 22
NBIX
Earnings call transcript
2021 Q4
11 Feb 22
NBIX
Earnings call transcript
2021 Q3
2 Nov 21
Latest ownership filings
4
ERIC BENEVICH
17 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Ingrid Delaet
3 Apr 24
4
Ingrid Delaet
25 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
4
ERIC BENEVICH
15 Mar 24
4
GEORGE J MORROW
15 Mar 24
4
RICHARD F POPS
15 Mar 24
4
Ingrid Delaet
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
91.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 501 |
Opened positions | 97 |
Closed positions | 32 |
Increased positions | 152 |
Reduced positions | 192 |
13F shares | Current |
---|---|
Total value | 10.23 tn |
Total shares | 91.17 mm |
Total puts | 411.60 k |
Total calls | 504.20 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 13.37 mm | $1.50 tn |
Vanguard | 9.56 mm | $1.08 tn |
STT State Street | 3.84 mm | $431.61 bn |
BLVGF Bellevue | 2.58 mm | $290.65 bn |
Point72 Asset Management | 2.58 mm | $290.04 bn |
MS Morgan Stanley | 1.92 mm | $216.46 bn |
JPM JPMorgan Chase & Co. | 1.81 mm | $203.76 bn |
JHG Janus Henderson | 1.72 mm | $193.17 bn |
Renaissance Technologies | 1.59 mm | $178.76 bn |
Geode Capital Management | 1.55 mm | $174.68 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Benevich Eric | Common Stock | Sell | Dispose S | No | Yes | 133.3646 | 12,587 | 1.68 mm | 40,778 |
15 Apr 24 | Benevich Eric | Common Stock | Option exercise | Acquire M | No | No | 81.05 | 12,587 | 1.02 mm | 53,365 |
15 Apr 24 | Benevich Eric | Common Stock | Sell | Dispose S | No | Yes | 133.3646 | 7,231 | 964.36 k | 40,778 |
15 Apr 24 | Benevich Eric | Common Stock | Option exercise | Acquire M | No | No | 81.49 | 7,231 | 589.25 k | 48,009 |
15 Apr 24 | Benevich Eric | NQSO Common Stock | Option exercise | Dispose M | No | No | 81.05 | 12,587 | 1.02 mm | 0 |
15 Apr 24 | Benevich Eric | NQSO Common Stock | Option exercise | Dispose M | No | No | 81.49 | 7,231 | 589.25 k | 26,292 |
1 Apr 24 | Ingrid Delaet | Common Stock | Sell | Dispose S | No | Yes | 137.3 | 272 | 37.35 k | 7,507 |
1 Apr 24 | Ingrid Delaet | Common Stock | Option exercise | Acquire M | No | No | 79.02 | 272 | 21.49 k | 7,779 |
1 Apr 24 | Ingrid Delaet | NQSO Common Stock | Option exercise | Dispose M | No | No | 79.02 | 272 | 21.49 k | 5,172 |
21 Mar 24 | Ingrid Delaet | Common Stock | Sell | Dispose S | No | Yes | 145.064 | 5,000 | 725.32 k | 7,507 |
News
Wells Fargo Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $170
24 Apr 24
Oppenheimer Maintains Outperform on Neurocrine Biosciences, Maintains $200 Price Target
24 Apr 24
HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $150 Price Target
24 Apr 24
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
23 Apr 24
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $147 Price Target
17 Apr 24
Press releases
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
24 Apr 24
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
16 Apr 24
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16 Apr 24
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
10 Apr 24
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
3 Apr 24